Bristol-Myers, Genentech settle Tecentriq suit

Bristol-Myers Squibb (NYSE:BMY), in an agreement with Roche’s (OTCQX:RHHBY) Genentech, agrees to drop a lawsuit that accused Tecentriq of infringing its patent for PD-1 inhibitors, Bloomberg reports, citing court filings in Wilmington, DE.

Details of the agreement weren’t disclosed.

So-called PD-1 inhibitors are antibodies that program a person’s own immune cells to identify and attack cancer cells.

Tecentriq’s U.S. sales of CHF 469M ($469.4M) in 2018 made up 0.6% of Roche’s revenue, according to Bloomberg data.

https://seekingalpha.com/news/3471573-bristol-myers-genentech-settle-tecentriq-suit